Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC

Summary

The purposes of this study in United Network for Organ Sharing (UNOS) Status 1B (or country equivalent) cardiac transplant candidates are to assess the safety and efficacy of Natrecor (nesiritide). The study will evaluate the drug's ability to prevent clinical worsening when administered as a 28-day continuous intravenous infusion in patients receiving standard care and continuous intravenous infusion of dobutamine or milrinone.

Timeline

Start

2006-09

Primary completion

2007-10

Completion

2007-10

Outcome

Outcome not reported

Stopped (Enrollment): “DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated due to slow enrollment”

Drugs

Indications